Clinical Trials
Page 5 • 11 itemsAccess global clinical trial data, regulatory updates, and competitive intelligence for strategic pharma R&D and investment decisions.
HSA Clinical Trial Modernization: Singapore's New Framework for CITDs
Singapore's innovative framework for Clinical Investigation of Therapeutic Devices (CITDs) aims to modernize clinical trials, enhancing drug safety and efficacy.
Zai Lab's ZL-1503 Bispecific Antibody Shows Promise for Rapid Itch Relief in Atopic Diseases
Zai Lab's ZL-1503, an IL-13/IL-31Rα bispecific antibody, demonstrates rapid itch relief and inflammation reduction in preclinical atopic disease studies.
Zai Lab's ZL-1503 Bispecific Antibody Shows Rapid Itch Relief in Atopic Disease Preclinical Data
Zai Lab presents promising preclinical data for ZL-1503, an IL-13/IL-31Rα bispecific antibody targeting rapid itch relief and inflammation reduction in atopic diseases.
Antengene Presents Three Novel Cancer Programs at AACR 2026: Next-Generation ADC and TCE Therapies Show Promise
Antengene Corporation unveiled three innovative cancer treatment programs at AACR 2026, featuring next-generation ADC and TCE technologies for oncology patients.
Antengene Presents Next-Generation ADC and AnTenGager TCE Programs at AACR 2026
Antengene showcases three novel oncology programs at AACR 2026, featuring next-generation ADC technology and AnTenGager T-cell engagers for cancer treatment.
Phantom Neuro Receives Approval for First Human Trial of Phantom X Neural Interface System
Phantom Neuro gets approval for first-in-human trial of Phantom X neural interface system in Australia, marking major milestone for prosthetic control technology.
Phrontline Biopharma's TJ106 Shows Promise Against HER2-Low and Drug-Resistant Cancers in Preclinical Studies
Phrontline Biopharma presents preclinical data for TJ106, a biparatopic HER2 ADC showing activity in HER2-low and resistant tumors at AACR 2026.
XellSmart Advances XS411 Parkinson's Cell Therapy to Phase II Trial After Positive Phase I Results
XellSmart launches multicenter Phase II trial for XS411, an iPSC-derived dopaminergic cell therapy for Parkinson's disease following encouraging Phase I data.
Telix Pharmaceuticals Doses First Patient in Phase 3 Trial of TLX101-Tx for Recurrent Glioblastoma
Telix begins Phase 3 IPAX-BrIGHT trial of TLX101-Tx, marking the first radiopharmaceutical therapy to reach Phase 3 for recurrent glioblastoma treatment.
AI-Powered Clinical Trial Matching: Accelerating Drug Development in China
AI-driven clinical trial matching is revolutionizing drug development in China, streamlining processes for new therapies and improving patient recruitment.
Australia Leads APAC Early Phase Trials: TGA Pathways Analysis 2024
Australia is at the forefront of APAC early phase trials, analyzing TGA pathways for drugs like Ozempic, enhancing diabetes treatment options in 2024.